Illumina News and Research

RSS

Illumina 2010 third quarter revenue increases 50% to $237.3 million

Illumina, Inc. today announced its financial results for the third quarter of 2010.

From Illumina, Inc. 27 Oct 2010

Helicos names Illumina and Life Technologies as additional defendants in lawsuit against Pacific Biosciences

Helicos BioSciences Corporation announced today that it has amended its lawsuit against Pacific Biosciences of California, Inc. for patent infringement by naming Illumina, Inc. and Life Technologies Corporation as additional defendants.

From Illumina, Inc. 25 Oct 2010

Agilent introduces SureSelect Kinome Target Enrichment Kit to focus next-generation sequencing studies

Agilent Technologies Inc. today introduced the SureSelect Kinome Target Enrichment Kit, enabling researchers to focus next generation sequencing studies on expressed kinases (the kinome). Researchers increasingly are looking at human kinases as a rich, proven source of biomarkers as well as potential drug targets for cancers and other diseases.

30 Sep 2010

Covaris enters co-marketing partnership with Illumina for DNA shearing technologies

Covaris Inc. today announced that it has signed a co-marketing agreement with Illumina, Inc. making Covaris DNA shearing technologies the recommended method of shearing with Illumina next-generation sequencing product lines, including HiSeq, HiScanSQ, and Genome Analyzer.

From Illumina, Inc. 29 Sep 2010

Scientists create human liver cells using stem cells

Emerging Healthcare Solutions President and CEO Cindy Morrissey said Tuesday that a recent study at the University of Cambridge seems to indicate that realistic stem cell therapies to replace diseased or damaged tissues may be closer than ever.

23 Sep 2010

Devil genome sequenced: Hope for endangered Tasmanian Devils

Tasmanian Devil Salem died at age seven but made a difference to her endangered species. Only 50 micrograms of her tissue was taken and processed by Australian genetic scientist Elizabeth Murchison, using new US technology, to produce the first devil genome sequence. As a result, the fight against devil facial tumor disease now has a draft DNA reference map. This was presented at a genetic conference in Hobart yesterday.

16 Sep 2010

Ambry Genetics acquires Illumina HiSeq 2000 Sequencing and BeadXpress Genotyping systems

Ambry Genetics, a global leader in genomic services, announced today that it has acquired the Illumina HiSeq 2000 Next Generation Sequencing System as well as received the first 510(K) approved Illumina BeadXpress Genotyping System. Ambry Genetics has been an early adapter of Illumina systems since late 2007 and has extensive experience as a Certified Service Provider.

26 Aug 2010

Agilent Technologies introduces SureSelect Human All Exon v2 Target Enrichment kit for cancer assay

Agilent Technologies Inc.today introduced the SureSelect Human All Exon v2 Target Enrichment kit, which was developed in close collaboration with the Broad Institute of MIT and Harvard. The kit, the 15th SureSelect product in Agilent's portfolio, is a single tube assay that allows researchers to streamline experiments by sequencing the expressed genome while discarding regions not of interest.

25 Aug 2010

Complete Genomics raises $39 million in Series E funding

Complete Genomics announced today that it has raised $39 million in its Series E funding round. New investor Sands Capital led this round of financing and was joined by existing investors Essex Woodlands, OVP Venture Partners, Prospect Venture Partners, OrbiMed Advisors, Highland Capital and Enterprise Partners.

20 Aug 2010

CLC bio, PSSC Labs announce new turnkey solution for full-genome assembly and analysis

Today, CLC bio and PSSC Labs announced a new turnkey solution, CLC Genomics Factory, for assembly, read mapping, and subsequent downstream analysis of very large amounts of high-throughput DNA and RNA sequencing data. Built as a high-performance bioinformatics appliance, CLC Genomics Factory comes in three different sizes with varying numbers of compute nodes, capable of processing the data output from up to 10 Illumina HiSeq2000 or 7 Life Technologies SOLiD 4 systems.

13 Aug 2010

Illumina launches TruSeq SBS Sequencing kit

Illumina, Inc. today announced the launch of its TruSeq SBS Sequencing kit that will enable high-quality paired end reads of 150 base pairs (bp), increase the output of high-quality base calls, and enhance throughput to greater than 95 Gigabases (Gb) of high-quality base pairs per run on Illumina's Genome Analyzer (GA) sequencing system.

From Illumina, Inc. 26 Jul 2010

SeqWright becomes first CSP for Agilent SureSelect Target Enrichment System

Agilent Technologies Inc. and SeqWright DNA Technology Services today announced that SeqWright is the first Certified Service Provider for the Agilent SureSelect Target Enrichment System for use with the next-generation AB SOLiD sequencing platform.

8 Jul 2010

NuGEN launches Encore NGS Library/Multiplex Systems and Ovation 3'-DGE System

NuGEN®, the provider of innovative RNA and DNA amplification and sample preparation technologies for breakthrough genomic analysis, today announced the introduction of its Encore NGS Library/Multiplex Systems and the Ovation 3'-DGE System. Together with the Ovation RNA-Seq System, launched in 2009, NuGEN is continuing to provide life sciences researchers with innovative and versatile sample preparation reagents that enable a broad range of Next Generation Sequencing (NGS) applications through fast, simple and scalable workflows.

11 Jun 2010

New pricing of $19,500 set for Illumina's individual genome sequencing service

Illumina, Inc. today announced a new price of $19,500 for its individual genome sequencing service. In addition, the company announced a price of $14,500 per genome for groups of five or more participants using the same physician. Individuals with serious medical conditions for whom whole-genome sequencing could provide potential direct clinical value will be eligible for special pricing of $9,500 per genome.

From Illumina, Inc. 4 Jun 2010

Illumina commences shipment of new HumanOmni2.5-Quad DNA Analysis BeadChip microarray

Illumina, Inc. today announced that it has begun shipping its new HumanOmni2.5-Quad DNA Analysis BeadChip (Omni2.5). This microarray contains millions of newly discovered genome-wide common and rare variants from the 1,000 Genomes Project (1kGP), selected to maximize its ability to detect new associations.

From Illumina, Inc. 2 Jun 2010

Texas A&M uses pGAP and IBM supercomputing technology to boost tuberculosis research

IBM today announced that Texas A&M University used IBM supercomputing technology to carry out potentially life-saving tuberculosis research at a rate more than four times faster than was previously possible.

2 Jun 2010

Various aspects of consumer genetics to be discussed at 2nd Annual Consumer Genetics Conference

At the 2nd Annual Consumer Genetics Conference taking place in Boston from June 2-4 at the Hynes Convention Center, these issues will be addressed and preeminent leaders from varying areas of expertise will provide perspectives on these crucial topics that are shaping the way we approach clinical medicine and helping to improve patient outcomes.

29 May 2010

Mount Sinai School of Medicine deploys Isilon scale-out NAS for DNA sequencing and analysis workflow

Isilon® Systems today announced that Mount Sinai School of Medicine's Genomics Institute and Department of Genetics and Genomic Sciences has deployed Isilon scale-out NAS as the primary repository for its next-generation DNA sequencing and analysis workflow.

27 May 2010

SiMoA technology measures individual PSA molecules in prostate cancer patients: Nature Biotechnology

Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company's proprietary technology that demonstrates an unprecedented sensitivity for measuring a biomarker for prostate cancer recurrence.

24 May 2010

FDA grants Illumina 510(k) clearance for VeraCode Genotyping Test for Factor V and Factor II

Illumina, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) market clearance for the VeraCode® Genotyping Test for Factor V (Leiden) and Factor II (Prothrombin).

From Illumina, Inc. 19 May 2010